Isabel Tecu, Principal, Charles River Associates

#179 What Have We Learned From Empirical Studies? Potential Antitrust Concerns Arising From Common Ownership

Posted 10 months ago Tagged

There is a growing interest in understanding the “ownership interests hypothesis,” i.e., whether investors holding […]

Adrian van den Hoven, Director General, Medicines for Europe

#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Posted 2 years ago Tagged

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]

Michael Kades, Director, Competition Policy, Washington Center for Equitable Growth

#76 What’s Ahead in Pharmaceutical Antitrust Enforcement? Taking Stock of Key Pharmaceutical Issues and Enforcement Actions

Posted 3 years ago Tagged

Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]